Prophylactic Antibiotics May Decrease Rate of Non-pancreatic Infection and UTI in Patients with Acute Pancreatitis

calendar
3 Feb, 20

Background

Although several clinical trials and guidelines indicate that prophylactic antibiotics are not beneficial in preventing infected necrosis and reducing the incidence of complications and death, some physicians still choose to administer prophylactic antibiotics to patients with acute pancreatitis (AP). It is unclear whether prophylactic antibiotics are beneficial in AP to prevent infected necrosis and reduce the incidence of death.

Aim

To assess whether antibiotic prophylaxis is beneficial in patients with AP. Researchers focused not only on mortality and morbidity but also on specific infections such as pneumonia, urinary tract infection (UTI), positive blood culture, and fungal infection.

Patients Profile

Patients with AP or severe AP (SAP) or acute necrotizing pancreatitis

Methods

  • The metanalysis included studies randomized control trials (11 RCTs) that
    • Assessed prophylactic use of antibiotics
    • written in any language
    • comprised of patients (N=747 participants) with AP or SAP or acute necrotizing pancreatitis
    • described the name and dose of antibiotics
    • Randomized control trials
Table 1: Characteristics of randomized controlled trials included in the metaanalysis

First

authors

Year

Study design

Clinical features

Number of

patients

(intervention/

control), n

Gender

(male/

female)

Antibiotics

and dosage

Time of

administration

(h)

Antibiotic

duration

(days)

Outcome∗

measures

Dellinger

et al

2007

RCT (multicenter)

Pancreatic necrosis on

CT scan

100

(50/50)

70/30

Meropenem (1 g, q8h)

<120

7–21

1,2,3,4

Garc?a-Barrasa

et al

2009

RCT (single-center)

Pancreatic necrosis on

CT scan

41

(22/19)

29/12

Ciprofloxacin (300 mg,

q12h)

48–72

10

1,2,3,4

Isenmann

et al

2004

RCT (multicenter)

Pancreatic necrosis on

CT scan; CRP > 150

mg/L

114

(58/56)

87/27

Ciprofloxacin (400 mg,

q12h), metronidazole

(500 mg, q12h)

<72

14–21

1,2,3,4

Nordback et al

2001

RCT (single-center)

Pancreatic necrosis on

CT scan

58

(25/33)

51/7

Imipenem (1 g, q8h)

<48

Not stated

1,2,3,4

Pederzoli et al

1993

RCT (multicenter)

Pancreatic necrosis on

CT scan

74

(41/33)

Not stated

Imipenem (0.5 g, q8h)

<72

14

1,2,3,4

Poropat

et al

2016

RCT (single-center)

Acute pancreatitis

APACHE II score >8

47

(23/24)

Not stated

Imipenem (0.5 g, q8h)

Not stated

10

1,2,4

Poropat

et al

2017

RCT (single-center)

Acute pancreatitis

APACHE II score  8

98

(49/49)

Not stated

Imipenem (0.5 g, q8h)

Not stated

10

1, 4

Rokke

et al

2007

RCT (multicenter)

Pancreatic necrosis on

CT scan; CRP >120

mg/L (24 h); CRP

73

(36/37)

49/24

Imipenem (0.5 g, q8h)

<72

5–7

1,2,3,4

Sainio

et al

1995

RCT (single-center)

>240 mg/L (48 h)

Low enhancement on

CT; CRP >120 mg/L

60

(30/30)

53/7

Cefuroxime (1.5 g, q8h)

<48

14

1,2,3

Schwarz

et al

1997

RCT (single-center)

Pancreatic necrosis on

CT scan

26

(13/13)

Not stated

Ofloxacin (200 mg,

q12h), metronidazole

(500 mg, q12h)

Not stated

10

1, 2

Xue

et al

2009

RCT (single-center)

>30% pancreatic

necrosis on CT scan

56 (29/27)

28/28

Imipenem (0.5 g, q8h)

<72

7–10

1,2,3,4

Meaning of numbers for outcome measures: 1: Death; 2: Infected pancreatic necrosis; 3: Surgical intervention; 4: Non-pancreatic infection; RCT: Randomized controlled trial; CT: Chemotherapy; CRP: C-reaction protein; APACHE II: Acute Physiology and Chronic Health Evaluation I.

 

  • Pooled analyses for infected pancreatic necrosis, mortality, surgical intervention, and non-pancreatic infection

Outcomes

  • Primary outcome parameters: the incidence of infected pancreatic necrosis and mortality
  • Secondary outcome parameters: the incidence of surgical intervention, non-pancreatic infection, pneumonia, UTI, positive blood culture, and fungal infection

Results

  • The intervention group included (prophylactic use of antibiotics, n = 376) and control group (n = 371).

Effect on the Incidence of infected Pancreatic necrosis and Mortality and Surgical Intervention

  • No significant differences were found regarding antibiotic prophylaxis concerning the incidence of
    • infected pancreatic necrosis (OR, 0.74; P = 0.13)
    • surgical intervention (OR, 0.92; P = 0.70)
    • morality (OR, 0.71; P = 0.16)

Effect on non-pancreatic infection Pneumonia, UTI, Positive blood culture, Fungal infection

  • The use of antibiotics was associated with a significant reduction in the incidence of non-pancreatic infections.
  • The overall OR was 0.59 (P = 0.004)
  • Prophylactic use of antibiotics did not reduce the incidence of pneumonia (OR = 0.61; P = 0.12) ,positive blood culture (OR = 0.61; P = 0.20), or fungal infection (OR = 0.95; P = 0.94)
  • However, antibiotic prophylaxis could reduce the incidence of UTI (OR = 0.44; P = 0.02)

Conclusions

  • Prophylactic antibiotics can reduce the incidence of non-pancreatic infection and UTI in patients with AP
  • Prophylactic antibiotics did not reduce rate of  infected pancreatic necrosis, mortality, surgical intervention, pneumonia, positive blood culture, and fungal infection.

Reference

Chinese Medical Journal 2020; 133;2: 213-220